Updated
Reviewed
Jun. 03, 2021

Appendix B: Drug Characteristics Tables

Appendix B, Table 1. Coformulated and Copackaged Antiretroviral Regimens

The following table includes dose recommendations for Food and Drug Administration (FDA)-approved coformulated and copackaged antiretroviral regimens. Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs included in these products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The products in this table are listed by drug class and arranged in alphabetical order by trade name within each class. 

Appendix B, Table 1. Coformulated Single-Tablet Regimens
Trade Name
(Abbreviations)		 ARV Drugs Included in the Regimen Dosing Recommendationa
INSTI plus Two NRTIs
Biktarvy
(BIC/TAF/FTC)		 Bictegravir 50 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg One tablet PO once daily
Genvoya
(EVG/c/TAF/FTC)		 Elvitegravir 150 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg One tablet PO once daily with food
Stribild
(EVG/c/TDF/FTC)		 Elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg One tablet PO once daily with food
Triumeq
(DTG/ABC/3TC)		 Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg One tablet PO once daily
INSTI plus One NRTI
Dovato
(DTG/3TC)		 Dolutegravir 50 mg/lamivudine 300 mg One tablet PO once daily
PI plus Two NRTIs
Symtuza
(DRV/c/TAF/FTC)		 Darunavir 800 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg One tablet PO once daily with food
NNRTI plus Two NRTIs
Atripla
(EFV/TDF/FTC)		 Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg One tablet PO once daily on an empty stomach, preferably at bedtime 
Complera
(RPV/TDF/FTC)		 Rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg One tablet PO once daily with a meal
Delstrigo
(DOR/TDF/3TC)		 Doravirine 100 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg One tablet PO once daily 
Odefsey
(RPV/TAF/FTC)		 Rilpivirine 25 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg One tablet PO once daily with a meal
Symfi
(EFV/TDF/3TC)		 Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg One tablet PO once daily on an empty stomach, preferably at bedtime
Symfi Lo
(EFV/TDF/3TC)		 Efavirenz 400 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg One tablet PO once daily on an empty stomach, preferably at bedtime
INSTI plus One NNRTI
Cabenuva
(CAB IM and RPV IM)

Cabenuva 600 mg/900 mg kit contains:

  • CAB 600 mg/3 mL vial and RPV 900 mg/3 mL vial

Cabenuva 400 mg/600 mg kit contains:

  • CAB 400 mg/2mL vial and RPV 600 mg/2 mL vial

Lead-in with Oral CAB and RPV:

  • (CAB 30 mg and RPV 25 mg) PO once daily with a meal for 4 weeks 

IM CAB and RPV: 

  • Loading dose: CAB 600 mg/3 mL IM × 1 dose and RPV 900 mg/3 mL IM × 1 dose 
  • Continuation phase: CAB 400 mg/2 mL IM every 4 weeks and RPV 600 mg/2 mL IM every 4 weeks
Juluca
(DTG/RPV)		 Dolutegravir 50 mg/rilpivirine 25 mg One tablet PO once daily with a meal
a For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 11 When no food restriction is listed, the product can be taken with or without food.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = orally; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

Appendix B: Drug Characteristics Tables

Appendix B, Table 1. Coformulated and Copackaged Antiretroviral Regimens

The following table includes dose recommendations for Food and Drug Administration (FDA)-approved coformulated and copackaged antiretroviral regimens. Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs included in these products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The products in this table are listed by drug class and arranged in alphabetical order by trade name within each class. 

Appendix B, Table 1. Coformulated Single-Tablet Regimens
Trade Name
(Abbreviations)		 ARV Drugs Included in the Regimen Dosing Recommendationa
INSTI plus Two NRTIs
Biktarvy
(BIC/TAF/FTC)		 Bictegravir 50 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg One tablet PO once daily
Genvoya
(EVG/c/TAF/FTC)		 Elvitegravir 150 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg One tablet PO once daily with food
Stribild
(EVG/c/TDF/FTC)		 Elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg One tablet PO once daily with food
Triumeq
(DTG/ABC/3TC)		 Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg One tablet PO once daily
INSTI plus One NRTI
Dovato
(DTG/3TC)		 Dolutegravir 50 mg/lamivudine 300 mg One tablet PO once daily
PI plus Two NRTIs
Symtuza
(DRV/c/TAF/FTC)		 Darunavir 800 mg/cobicistat 150 mg/tenofovir alafenamide 10 mg/emtricitabine 200 mg One tablet PO once daily with food
NNRTI plus Two NRTIs
Atripla
(EFV/TDF/FTC)		 Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg One tablet PO once daily on an empty stomach, preferably at bedtime 
Complera
(RPV/TDF/FTC)		 Rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg One tablet PO once daily with a meal
Delstrigo
(DOR/TDF/3TC)		 Doravirine 100 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg One tablet PO once daily 
Odefsey
(RPV/TAF/FTC)		 Rilpivirine 25 mg/tenofovir alafenamide 25 mg/emtricitabine 200 mg One tablet PO once daily with a meal
Symfi
(EFV/TDF/3TC)		 Efavirenz 600 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg One tablet PO once daily on an empty stomach, preferably at bedtime
Symfi Lo
(EFV/TDF/3TC)		 Efavirenz 400 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg One tablet PO once daily on an empty stomach, preferably at bedtime
INSTI plus One NNRTI
Cabenuva
(CAB IM and RPV IM)

Cabenuva 600 mg/900 mg kit contains:

  • CAB 600 mg/3 mL vial and RPV 900 mg/3 mL vial

Cabenuva 400 mg/600 mg kit contains:

  • CAB 400 mg/2mL vial and RPV 600 mg/2 mL vial

Lead-in with Oral CAB and RPV:

  • (CAB 30 mg and RPV 25 mg) PO once daily with a meal for 4 weeks 

IM CAB and RPV: 

  • Loading dose: CAB 600 mg/3 mL IM × 1 dose and RPV 900 mg/3 mL IM × 1 dose 
  • Continuation phase: CAB 400 mg/2 mL IM every 4 weeks and RPV 600 mg/2 mL IM every 4 weeks
Juluca
(DTG/RPV)		 Dolutegravir 50 mg/rilpivirine 25 mg One tablet PO once daily with a meal
a For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 11 When no food restriction is listed, the product can be taken with or without food.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = orally; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

Download Guidelines

Related Content